ArticleEMBO reports2011
Reprogramming of mouse and human somatic cells by high-performance engineered factors.
Article in EMBO reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 85 citations in OpenAlex.
- Review
- Induced pluripotent stem cell reprogramming: methodological evolution and challenges in clinical translation.Frontiers in cell and developmental biology · 2026Review
- Enhanced Activities of OCT4 and SOX2 Promote Epigenetic Reprogramming by Shortening G1 Phase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cell reprogramming: methods, mechanisms and applications.Cell regeneration (London, England) · 2025Review
- Engineering mouse cell fate controller by rational design.Nature communications · 2024Article
- Mesenchymal stem cells derived from patients with premature aging syndromes display hallmarks of physiological aging.Life science alliance · 2022Article
- Fast and Efficient Mouse Pluripotency Reprogramming Using a Chemically-Defined Medium.Methods and protocols · 2022Article
- Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments.International journal of medical sciences · 2021Review
- Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications.Stem cell reviews and reports · 2020Review
- Excluding Oct4 from Yamanaka Cocktail Unleashes the Developmental Potential of iPSCs.Cell stem cell · 2019Article
- Oct4-mediated reprogramming induces embryonic-like microRNA expression signatures in human fibroblasts.Scientific reports · 2019Article
- Modeling blood diseases with human induced pluripotent stem cells.Disease models & mechanisms · 2019Review
- Nuclear-cytoplasmic shuttling of class IIa histone deacetylases regulates somatic cell reprogramming.Cell regeneration (London, England) · 2019Article
- Exploring induced pluripotency in human fibroblasts via construction, validation, and application of a gene regulatory network.PloS one · 2019Article
- NCoR/SMRT co-repressors cooperate with c-MYC to create an epigenetic barrier to somatic cell reprogramming.Nature cell biology · 2018Article
- OCT4 and SOX2 Work as Transcriptional Activators in Reprogramming Human Fibroblasts.Cell reports · 2017Article
- Virus-Like Particles Derived from HIV-1 for Delivery of Nuclear Proteins: Improvement of Production and Activity by Protein Engineering.Molecular biotechnology · 2017Article
- Distinctive Klf4 mutants determine preference for DNA methylation status.Nucleic acids research · 2016Article
- Induced Pluripotent Stem Cells: Generation Strategy and Epigenetic Mystery behind Reprogramming.Stem cells international · 2016Review
- A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects.Frontiers in aging neuroscience · 2016Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reprogramming somatic cells to become induced pluripotent stem cells (iPSCs) by using defined factors represents an important breakthrough in biology and medicine, yet remains inefficient and poorly understood. We therefore devised synthetic factors by fusing the VP16 transactivation domain to OCT4 (also known as Pou5f1), NANOG and SOX2, respectively. These synthetic factors could reprogramme both mouse and human fibroblasts with enhanced efficiency and accelerated kinetics. Remarkably, Oct4-VP16 alone could efficiently reprogramme mouse embryonic fibroblasts (MEFs) into germline-competent iPSCs. Furthermore, episomally delivered synthetic factors could reproducibly generate integration-free iPSCs from MEFs with enhanced efficiency. Our results not only demonstrate the feasibility of engineering more potent reprogramming factors, but also suggest that transcriptional reactivation of OCT4 target genes might be a rate-limiting step in the conversion of somatic cells to pluripotent cells. Synthetic factor-based reprogramming might lead to a paradigm shift in reprogramming research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.